An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Trial Profile

An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Ewing's sarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms BERNIE
  • Sponsors Roche
  • Most Recent Events

    • 02 Jan 2018 Planned End Date changed from 8 Jun 2019 to 30 Apr 2019.
    • 26 Jul 2017 Planned End Date changed from 1 May 2019 to 8 Jun 2019.
    • 12 Jul 2017 Primary endpoint (Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment) has not been met, as per results published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top